Cargando…

Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status

Insensitivity to platinum, either through inherent or acquired resistance, is a major clinical problem in the treatment of many solid tumors. Here, we explored the therapeutic potential of diethyldithiocarbamate (DDC), pyrithione (Pyr), plumbagin (Plum), 8-hydroxyquinoline (8-HQ), clioquinol (CQ) co...

Descripción completa

Detalles Bibliográficos
Autores principales: Wehbe, Mohamed, Lo, Cody, Leung, Ada W. Y., Dragowska, Wieslawa H., Ryan, Gemma M., Bally, Marcel B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694505/
https://www.ncbi.nlm.nih.gov/pubmed/28733701
http://dx.doi.org/10.1007/s10637-017-0488-2
_version_ 1783280146571067392
author Wehbe, Mohamed
Lo, Cody
Leung, Ada W. Y.
Dragowska, Wieslawa H.
Ryan, Gemma M.
Bally, Marcel B.
author_facet Wehbe, Mohamed
Lo, Cody
Leung, Ada W. Y.
Dragowska, Wieslawa H.
Ryan, Gemma M.
Bally, Marcel B.
author_sort Wehbe, Mohamed
collection PubMed
description Insensitivity to platinum, either through inherent or acquired resistance, is a major clinical problem in the treatment of many solid tumors. Here, we explored the therapeutic potential of diethyldithiocarbamate (DDC), pyrithione (Pyr), plumbagin (Plum), 8-hydroxyquinoline (8-HQ), clioquinol (CQ) copper complexes in a panel of cancer cell lines that differ in their sensitivity to platins (cisplatin/carboplatin) using a high-content imaging system. Our data suggest that the copper complexes were effective against both platinum sensitive (IC(50) ~ 1 μM platinum) and insensitive (IC(50) > 5 μM platinum) cell lines. Furthermore, copper complexes of DDC, Pyr and 8-HQ had greater therapeutic activity compared to the copper-free ligands in all cell lines; whereas the copper-dependent activities of Plum and CQ were cell-line specific. Four of the copper complexes (Cu(DDC)(2), Cu(Pyr)(2), Cu(Plum)(2) and Cu(8-HQ)(2)) showed IC(50) values less than that of cisplatin in all tested cell lines. The complex copper DDC (Cu(DDC)(2)) was selected for in vivo evaluation due to its low nano-molar range activity in vitro and the availability of an injectable liposomal formulation. Liposomal (Cu(DDC)(2)) was tested in a fast-growing platinum-resistant A2780-CP ovarian xenograft model and was found to achieve a statistically significant reduction (50%; p < 0.05) in tumour size. This work supports the potential use of copper-based therapeutics to treat cancers that are insensitive to platinum drugs.
format Online
Article
Text
id pubmed-5694505
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-56945052017-11-30 Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status Wehbe, Mohamed Lo, Cody Leung, Ada W. Y. Dragowska, Wieslawa H. Ryan, Gemma M. Bally, Marcel B. Invest New Drugs Preclinical Studies Insensitivity to platinum, either through inherent or acquired resistance, is a major clinical problem in the treatment of many solid tumors. Here, we explored the therapeutic potential of diethyldithiocarbamate (DDC), pyrithione (Pyr), plumbagin (Plum), 8-hydroxyquinoline (8-HQ), clioquinol (CQ) copper complexes in a panel of cancer cell lines that differ in their sensitivity to platins (cisplatin/carboplatin) using a high-content imaging system. Our data suggest that the copper complexes were effective against both platinum sensitive (IC(50) ~ 1 μM platinum) and insensitive (IC(50) > 5 μM platinum) cell lines. Furthermore, copper complexes of DDC, Pyr and 8-HQ had greater therapeutic activity compared to the copper-free ligands in all cell lines; whereas the copper-dependent activities of Plum and CQ were cell-line specific. Four of the copper complexes (Cu(DDC)(2), Cu(Pyr)(2), Cu(Plum)(2) and Cu(8-HQ)(2)) showed IC(50) values less than that of cisplatin in all tested cell lines. The complex copper DDC (Cu(DDC)(2)) was selected for in vivo evaluation due to its low nano-molar range activity in vitro and the availability of an injectable liposomal formulation. Liposomal (Cu(DDC)(2)) was tested in a fast-growing platinum-resistant A2780-CP ovarian xenograft model and was found to achieve a statistically significant reduction (50%; p < 0.05) in tumour size. This work supports the potential use of copper-based therapeutics to treat cancers that are insensitive to platinum drugs. Springer US 2017-07-21 2017 /pmc/articles/PMC5694505/ /pubmed/28733701 http://dx.doi.org/10.1007/s10637-017-0488-2 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Preclinical Studies
Wehbe, Mohamed
Lo, Cody
Leung, Ada W. Y.
Dragowska, Wieslawa H.
Ryan, Gemma M.
Bally, Marcel B.
Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
title Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
title_full Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
title_fullStr Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
title_full_unstemmed Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
title_short Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
title_sort copper (ii) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status
topic Preclinical Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694505/
https://www.ncbi.nlm.nih.gov/pubmed/28733701
http://dx.doi.org/10.1007/s10637-017-0488-2
work_keys_str_mv AT wehbemohamed copperiicomplexesofbidentateligandsexhibitpotentanticanceractivityregardlessofplatinumsensitivitystatus
AT locody copperiicomplexesofbidentateligandsexhibitpotentanticanceractivityregardlessofplatinumsensitivitystatus
AT leungadawy copperiicomplexesofbidentateligandsexhibitpotentanticanceractivityregardlessofplatinumsensitivitystatus
AT dragowskawieslawah copperiicomplexesofbidentateligandsexhibitpotentanticanceractivityregardlessofplatinumsensitivitystatus
AT ryangemmam copperiicomplexesofbidentateligandsexhibitpotentanticanceractivityregardlessofplatinumsensitivitystatus
AT ballymarcelb copperiicomplexesofbidentateligandsexhibitpotentanticanceractivityregardlessofplatinumsensitivitystatus